Stock Price

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

Primoris Services Corp. posted a record $7.6B revenue for 2025, but a Q4 profit dip and project hurdles hint at challenges in its booming renewables arm.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

A 14th-century Scottish castle is set for a modern makeover as MDJM LTD bets on turning the historic Fernie Castle into a major animation art gallery.

After a period of uncertainty, the digital asset firm has regained compliance with Nasdaq's bid price rule, a key step for its institutional ambitions.

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

Despite a stock dip, Select Water Solutions' major offering signals a strategic push for growth in water recycling, acquisitions, and infrastructure.

Seagate retires $600M in debt for cash and stock. A strategic move to fortify its balance sheet, but what does the share dilution mean for investors?

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Facing delisting, the Singaporean tech firm enacts a 1-for-20 reverse split. Is it a lifeline or a sign of deeper financial troubles ahead?

CRCD reports a 4.3% annual return and a higher share price, while shifting its investment model to better support Quebec’s entrepreneurial ecosystem.

The crypto ATM giant is executing a 1:7 reverse stock split to boost its share price. Is it a savvy strategic reset or a sign of deeper troubles?

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.